Advertisement
Canada markets open in 4 hours 27 minutes
  • S&P/TSX

    22,269.12
    +197.42 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.82 (+1.51%)
     
  • CAD/USD

    0.7323
    -0.0016 (-0.22%)
     
  • CRUDE OIL

    77.16
    +0.17 (+0.22%)
     
  • Bitcoin CAD

    94,409.78
    +1,951.27 (+2.11%)
     
  • CMC Crypto 200

    1,492.89
    +24.96 (+1.70%)
     
  • GOLD FUTURES

    2,345.90
    +0.10 (+0.00%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     
  • NASDAQ futures

    18,668.75
    +77.75 (+0.42%)
     
  • VOLATILITY

    13.24
    +0.32 (+2.48%)
     
  • FTSE

    8,305.32
    +29.94 (+0.36%)
     
  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     
  • CAD/EUR

    0.6753
    -0.0009 (-0.13%)
     

Harrow to Present at Two Investor Conferences in May

NASHVILLE, Tenn., May 15, 2024--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:

B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA)
Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024

Craig-Hallum 21st Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 29, 2024

ADVERTISEMENT

Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515334076/en/

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737